Trikalinos Thomas A, Chung Mei, Lau Joseph, Ip Stanley
Tufts Evidence-Based Practice Center and Center for Clinical Evidence Synthesis, Institute for Clinical Research and Health Policy Studies, Boston, Massachusetts 02111, USA.
Pediatrics. 2009 Oct;124(4):1162-71. doi: 10.1542/peds.2008-3545. Epub 2009 Sep 28.
Severe neonatal hyperbilirubinemia is associated with chronic bilirubin encephalopathy (kernicterus).
To systematically review the effectiveness of specific screening modalities to prevent neonatal bilirubin encephalopathy.
We identified studies through Medline searches, perusing reference lists and by consulting with US Preventive Services Task Force lead experts. We included English-language publications evaluating the effects of screening for bilirubin encephalopathy using early total serum bilirubin (TSB), transcutaneous bilirubin (TcB) measurements, or risk scores. Severe hyperbilirubinemia was used as a surrogate for possible chronic bilirubin encephalopathy, because no studies directly evaluated the latter as an outcome. We calculated the sensitivity and specificity of early TSB, TcB measurements, or risk scores in detecting hyperbilirubinemia.
Ten publications (11 studies) were eligible. Seven (2 prospective) studies evaluated the ability of risk factors (n = 3), early TSB (n = 3), TcB (n = 2), or combinations of risk factors and early TSB (n = 1) to predict hyperbilirubinemia (typically TSB > 95th hour-specific percentile 24 hours to 30 days postpartum). Screening had good ability to detect hyperbilirubinemia: reported area-under-the-curve values ranged between 0.69 and 0.84, and reported sensitivities and specificities suggested similar diagnostic ability. Indirect evidence from 3 descriptive uncontrolled studies suggests favorable associations between initiation of screening and decrease in hyperbilirubinemia rates, and rates of treatment or readmissions for hyperbilirubinemia compared with the baseline of no screening. No study assessed harms of screening.
Effects of screening on the rates of bilirubin encephalopathy are unknown. Although screening can predict hyperbilirubinemia, there is no robust evidence to suggest that screening is associated with favorable clinical outcomes.
重度新生儿高胆红素血症与慢性胆红素脑病(核黄疸)相关。
系统评价特定筛查方式预防新生儿胆红素脑病的有效性。
我们通过检索Medline、查阅参考文献列表以及咨询美国预防服务工作组的主要专家来确定研究。我们纳入了评估使用早期总血清胆红素(TSB)、经皮胆红素(TcB)测量或风险评分筛查胆红素脑病效果的英文出版物。由于没有研究直接将慢性胆红素脑病作为结局进行评估,因此将重度高胆红素血症用作可能的慢性胆红素脑病的替代指标。我们计算了早期TSB、TcB测量或风险评分在检测高胆红素血症方面的敏感性和特异性。
10篇出版物(11项研究)符合条件。7项(2项前瞻性)研究评估了风险因素(n = 3)、早期TSB(n = 3)、TcB(n = 2)或风险因素与早期TSB组合(n = 1)预测高胆红素血症(通常为产后24小时至30天TSB >第95小时特定百分位数)的能力。筛查具有良好的检测高胆红素血症的能力:报告的曲线下面积值在0.69至0.84之间,报告的敏感性和特异性表明诊断能力相似。3项描述性非对照研究的间接证据表明,与未筛查的基线相比,开始筛查与高胆红素血症发生率降低、高胆红素血症治疗或再入院率之间存在有利关联。没有研究评估筛查的危害。
筛查对胆红素脑病发生率的影响尚不清楚。虽然筛查可以预测高胆红素血症,但没有有力证据表明筛查与良好的临床结局相关。